AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03504410
Drug: Mitoxantrone, Etoposide and Cytarabine
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6
Trial: NCT03504410
Drug: Fludarabine, Cytarabine, Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5
Trial: NCT00003683
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03784066
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative.
Trial: NCT06544590
Drug: Betahistine Mesylate tablet
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg 3 times a day.
Trial: NCT00168298
Drug: 700 µg Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
Trial: NCT00369356
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bare metal stenting with administration of oral prednisone as described in the protocol
Trial: NCT01422291
Drug: paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 gr
Trial: NCT01422291
Drug: morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1mg/kg intravenous in 100 ml serum physiologic
Trial: NCT01422291
Drug: Dexketoprofen
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg
Trial: NCT00168298
Drug: 350 µg Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 350 µg Dexamethasone intravitreal implant administered on Day 0.
Trial: NCT01662895
Drug: Deferoxamine
RxNorm normalized name: Deferoxamine
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
Trial: NCT01415427
Drug: BMN 110 - Weekly
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.~In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Trial: NCT01415427
Drug: BMN 110 - Every Other Week
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.~In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo.
Trial: NCT01797900
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
Trial: NCT01797900
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
Trial: NCT02973737
Drug: pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg once daily
Trial: NCT03824808
Drug: Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine Hydrochloride and 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution prepared from lidocaine hydrochloride and dextrose in water for injection.
Trial: NCT03824808
Drug: 0.9% Sodium Chloride Injection
RxNorm normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride Injection USP is sterile, nonpyrogenic, isotonic and contains no bacteriostatic or antimicrobial agents.
Trial: NCT00586495
Drug: Sorafenib (Nexavar, BAY43-9006)
RxNorm normalized name: sorafenib 200 MG [Nexavar]
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 200 mg tablets (400 mg \[2 x 200 mg tablets\] twice daily \[bid\] or 400 mg once daily \[od\] or 400 mg every other day \[qod\]) administered orally
Trial: NCT00705783
Drug: Aripiprazole depot
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
Trial: NCT04049045
Drug: Empagliflozin 25 mg
RxNorm normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 25 mg film-coated tablets, for oral use administered once daily for 5 days in addition to routinely administered (weight adjusted) intravenous furosemide
Trial: NCT00579813
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
Trial: NCT00454493
Drug: Omacor (omega-3-acid ethyl esters)
RxNorm normalized name: Omega-3-Acid Ethyl Esters
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02432235
Drug: Camidanlumab tesirine
RxNorm normalized name: Camidanlumab tesirine
DrugBank: Camidanlumab tesirine (DB16411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion.
Trial: NCT00401752
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00401752
Drug: Ranitidine
RxNorm normalized name: Ranitidine
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00522587
Drug: Fixed sevoflurane dose 1
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 1 of sevoflurane
Trial: NCT00522587
Drug: Fixed sevoflurane dose 2
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 2 of sevoflurane
Trial: NCT00522587
Drug: Fixed sevoflurane dose 3
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 3 of sevoflurane
Trial: NCT00522587
Drug: Fixed sevoflurane dose 4
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 4 of sevoflurane
Trial: NCT01791751
Drug: Clomifene Citrate
RxNorm normalized name: Clomifene citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate 100 mg daily for 5 days
Trial: NCT00522587
Drug: Fixed sevoflurane dose 5
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 5 of sevoflurane
Trial: NCT00522587
Drug: Fixed sevoflurane dose 6
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 6 of sevoflurane
Trial: NCT00084201
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00084201
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01888042
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg (1 tablet of 10 mg)
Trial: NCT01923129
Drug: Prazosin given 6 hours prior to catheter removal in the 24 hour group
RxNorm normalized name: prazosin 6 MG
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
Trial: NCT04538794
Drug: CDX-0159
RxNorm normalized name: Immunoglobulin G1 [233-alanine,234-glutamine,251-tyrosine,253-threonine,255-glutamic acid,321-glutamine,de-C-terminal-lysine], anti-(human receptor tyrosine kinase KIT extracellular domain) (human-Mus musculus monoclonal CDX-0159 γ1-chain), disulfide wi
DrugBank: Barzolvolimab (DB18934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT03106623
Drug: ONO-8577
RxNorm normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of ONO-8577 once a daily for 4 weeks
Trial: NCT03106623
Drug: solifenacin succinate + mirabegron
RxNorm normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
Trial: NCT03596567
Drug: Glasdegib single 100 mg dose in normal healthy subjects
RxNorm normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
Trial: NCT03596567
Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
RxNorm normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Trial: NCT03596567
Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
RxNorm normalized name: glasdegib 100 MG
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
Trial: NCT03273153
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
Trial: NCT03273153
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab 840 mg as IV infusion once in every 2 weeks.
Trial: NCT03273153
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
Trial: NCT02115204
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02115204
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02115204
Drug: 5-fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01937234
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.~Maximum of 3 doses.
Trial: NCT04453046
Drug: Pembrolizumab 200mg IV
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg IV will be administered every 21 days. One cycle is 21 days. All patients will be treated with Pembrolizumab for up to 34 cycles
Trial: NCT03017170
Drug: Dried Cranberry
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit.
Trial: NCT00796276
Drug: IR OROS paliperidone and ER OROS paliperidone
RxNorm normalized name: paliperidone Extended Release Oral Tablet
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01066598
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
Trial: NCT01838681
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
Trial: NCT00298415
Drug: Paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
Trial: NCT00298415
Drug: Monotherapy (gemcitabine or vinorelbine)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
Trial: NCT02067611
Drug: X0002
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Parallel Assignment
Trial: NCT00376285
Drug: Fenofibrate
RxNorm normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03655080
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Dose 15 mg/m\^2~* Should be administered by IV over 30 minutes
Trial: NCT03155620
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03155620
Drug: Erdafitinib
RxNorm normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03155620
Drug: Larotrectinib Sulfate
RxNorm normalized name: Larotrectinib sulfate
DrugBank: Larotrectinib (DB14723)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO or via nasogastric- or gastric-tube
Trial: NCT03155620
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03155620
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03155620
Drug: Samotolisib
RxNorm normalized name: Samotolisib
DrugBank: LY-3023414 (DB12167)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03155620
Drug: Selpercatinib
RxNorm normalized name: Selpercatinib
DrugBank: Selpercatinib (DB15685)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT03897621
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tranexamic acid will be administered intravenously after induction of anesthesia (a bolus of 10 mg/kg or maximal dose of 1g).
Trial: NCT00191750
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03155620
Drug: Selumetinib Sulfate
RxNorm normalized name: selumetinib sulfate
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03155620
Drug: Tazemetostat
RxNorm normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03155620
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO or via nasogastric or gastric tube
Trial: NCT03155620
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive PO
Trial: NCT03155620
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00778882
Drug: VM106
RxNorm normalized name: Valsartan and Metoprolol
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Autologous hematopoietic stem cells with MT-gp91 retroviral vector
Trial: NCT04663204
Drug: Sparsentan
RxNorm normalized name: SPARSENTAN
DrugBank: Sparsentan (DB12548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose of 400 mg daily
Trial: NCT00242827
Drug: Oral CEP-701
RxNorm normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00058955
Drug: sodium oxybate, triazolam and pentobarbital
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium oxybate, triazolam and pentobarbital
Trial: NCT00873639
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Trial: NCT00873639
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
Trial: NCT02417298
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
Trial: NCT02233985
Drug: 0.9% Sodium Chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Trial: NCT02233985
Drug: 3% Sodium Chloride
RxNorm normalized name: Dextrose 5% and 0.3% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules 80mg
RxNorm normalized name: lipase
DrugBank: Metacavir (DB19084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules 80mg
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules 160mg
RxNorm normalized name: lipase
DrugBank: Metacavir (DB19084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules 160mg
Trial: NCT00285727
Drug: Ropinirole CR
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03757910
Drug: 11C-PIB
RxNorm normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This radiotracer will be used to detect amyloid. Participants will be injected with an intravenous bolus of up to 5-15 mCi.
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules 320mg
RxNorm normalized name: lipase
DrugBank: Metacavir (DB19084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules 320mg
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 240mg
RxNorm normalized name: dimethyl fumarate
DrugBank: Metacavir (DB19084)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules Placebo 240mg
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 160mg
RxNorm normalized name: lipase
DrugBank: Metacavir (DB19084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules Placebo 160mg
Trial: NCT02965859
Drug: Metacavir Enteric-coated Capsules Placebo 320mg
RxNorm normalized name: lipase
DrugBank: Metacavir (DB19084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacavir Enteric-coated Capsules Placebo 320mg
Trial: NCT02965859
Drug: Adefovir Dipivoxil Capsule10mg
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir Dipivoxil Capsule10mg
Trial: NCT02965859
Drug: Adefovir Dipivoxil Capsule Placebo 10mg
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir Dipivoxil Capsule Placebo 10mg